11 Cheap NYSE Stocks to Invest in According to Hedge Funds

9. Pfizer Inc. (NYSE:PFE)

Forward P/E Ratio as of April 8: 7.7

Number of Hedge Fund Holders: 92

Pfizer Inc. (NYSE:PFE) specializes in biopharmaceutical products. It offers medicines and vaccines. For cardiovascular and migraine, it has the Eliquis, Nurtec ODT/Vydura, Zavzpret, and Premarin family brands. For infectious diseases with unmet medical needs, it has the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands. For COVID-19 prevention and treatment, and potential future mRNA and antiviral products, it has the Comirnaty and Paxlovid brands.

The company’s treatment for advanced urothelial cancer, which is Padcev combined with pembrolizumab, is leading in the US with the potential to reach 3x more patients. Braftovi/Mektovi have also experienced a 27% global sales increase year-over-year, which is supported by new data showing improved survival rates in colorectal cancer. Lorbrena has become a standard lung cancer treatment with a 37% global sales increase. All of these are treatments in the company’s oncology segment.

For further expansions in the oncology pipeline, there are ongoing Phase 3 trials for sigvotatug vedotin in lung cancer. A Phase 3 readout for multiple myeloma is also expected. In 2025, the company will aim for multiple regulatory approvals and Phase 3 results. Recent positive Phase 3 results for breast cancer therapy vepdegestrant, combined with FDA Fast Track designation, highlight Pfizer Inc.’s (NYSE:PFE) commitment to innovation and strong financial performance.